Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Pfizer is fine. The DM article was written by someone with no understanding of the trial.
The comment was re Astra/Oxford so why title the thread Pfizer? Creates unnecessary confusion.
Axe, thank you for your comment as well. Was a late night and I missed your insightful comment.
Thank you Phoenix. I can now literally go to sleep well tonight !
SYN needs to be careful not to price itself out of the market. I thought I saw a headline late last week stating the the UK government had struck a deal to acquire a therapeutic conditional on the trial's successful conclusion (bamlanivimab?) but now I can't find the article. Regardless, my point still holds.
Realistically, I can only see it being used in cases where patients have been hospitalised.
@Hurtle, thanks for sharing the links. While I disagree with many of the claims, this progresses the conversation. In regards to the links that you have provided though, several dubious items stand out:
1. None of the sources that you site support the claim that "all they are now doing is causing strep throat, chest infections, skin rashes and"
2. The chief champion of the anti-mask lobby, Dr. Roger Hodkinson, is also in the "covid is a bad flu" camp which if you google "differences between influenza and covid", you would realise shows a lack of scientific understanding of the virus on his part.
3. While technocracy link was perhaps the most useful of the 3 links, it is a mixed bag of already accepted conventions and misunderstandings/misrepresentations of results from the studies cited.
Ex: Accepted Convention - those with certain medical conditions should be exempt from wearing masks (such as women who are pregnant). We know this already.
Ex: Accepted Convention - wearing a mask while exercising will rob you of needed oxygen. No one is being told to wear a mask while jogging...unless they are jogging while on a train or bus.
Ex: Misrepresentation of studies cited in the section "Risks of N95" - The study is not in regards to the efficacy of wearing a mask...that is not in question. Rather, the study examines the risk to the healthcare worker from indirect infection due to build up of virus on the mask. This suggests that without the mask, the virus that would have otherwise been breathed in, has accumulated on the mask and that care must be taken re discarding or disinfecting the mask after use.
Ex: Misrepresentation of studies cited in the section "Risks of surgical masks"...similar to N95.
hope2gain...can you provide a source or link to where you got that information? I have yet to find a link to a research study claiming this. I do get plenty of twitter and FB links from unknowns though!
$3000 per course is steep. Having Phase 3 results will make this more palatable.
The shelf life question was mine! lol
BIGXPX...thank you for sharing the link!
The link also states quite clearly "It is emphasized that the study did not examine the function of the masks as a source control, ie. to limit infection from an infected person wearing a mask to others. The study also did not elucidate the effect of bandages in situations where it is not possible to maintain the social distance.
It should therefore be emphasized that these results cannot be used to raise doubts that the widespread use of masks outside of healthcare can be an effective means of reducing SARS-CoV-2 infections. "
That is a terrible reason to deprive someone of a life-improving therapeutic. I'm surprised SYN doesn't hand out tablets to address this.
Excellent points, Elsol.
" But i believe we can mark our's up a little. Reason for that is that 17% of phase III'S fail due to safety and 22% due to lack of funding and I don't see those factors as an issue in the case of SNG."...this is a very good point.
HarChris, agree. In addition, I do like looking at the results of these studies because I see them partially reflecting the advances in research (or challenges) within these areas of medicine.
Killing time while waiting for P3 progress, I read up on success rates of trials and found a few studies. Which category does SYN's trial fall under? If infectious disease, then I like the odds!
https://www.acsh.org/news/2020/06/11/clinical-trial-success-rates-phase-and-therapeutic-area-14845
Thanks ChrisToffer.
Thank you. Excellent article and does a great job of describing how Interferons fit into the picture.
The update states that the trial has changed from open (masking, i.e. every knows that you are taking the treatment and therefore introduces all sorts of bias) to triple blind which I interpret as a step towards a more formalized approach to obtaining government approval. This is a good thing, right?